Introduction
============

Multidrug resistance (MDR) is the main cause of chemotherapeutic treatment failure in cancer patients. As a difficult problem, combating MDR cancer has always been an important mission of oncotherapy. The mechanisms of MDR are complex and obscure ([@b1-ijo-51-01-0257],[@b2-ijo-51-01-0257]). The major mechanism of MDR involves the overexpression of ATP-binding cassette (ABC) transporters. The ABC family of transporters comprises 49 members that are subdivided into seven subfamilies, ABC-A to ABC-G, based on their sequences and structures. Among known ABC transporters, ABCB1, ABCC1 and ABCG2 are the most influential members in MDR cancer ([@b3-ijo-51-01-0257],[@b4-ijo-51-01-0257]). ABCB1 (P-glycoprotein), encoded by the MDR1 gene, is a 170-kDa apical plasma membrane protein comprising two homologous halves, each containing an ATP-binding domain and six transmembrane helices ([@b5-ijo-51-01-0257],[@b6-ijo-51-01-0257]). ABCB1 is an ATP-dependent drug efflux pump that can transport a wide range of amphipathic and hydrophobic anticancer drugs, such as doxorubicin (DOX), vincristine (VCR), paclitaxel, epipodophyllotoxins, anthracyclines and taxanes ([@b7-ijo-51-01-0257]). Thus, antitumor agents that are ABCB1 substrates and are used in long-term treatment subsequently stimulate cancer cells to upregulate the ABCB1 mRNA copy number. The overexpression of ABCB1 results in decreased intracellular antineoplastic drug concentrations to sub-toxic levels. Thus, resensitizing MDR cancer cells to anticancer drugs using inhibitors that block the efflux system may be a successful chemotherapeutic strategy. However, in the past three decades, most ABCB1 modulators have failed in clinical trials due to their low binding affinities, excessive toxicity or non-specificity ([@b8-ijo-51-01-0257]--[@b12-ijo-51-01-0257]). Thus, the identification of new ABCB1 transporter inhibitors with lower toxicity but greater potency and specificity is extremely urgent.

Uncaria, a traditional Chinese medicine, is a member of the *Uncaria rhynchophylla (Miq.)* Jacks. family and is used to treat neoplastic diseases, various cerebrovascular diseases, nervous disorders and symptoms associated with hypertension, epilepsy, stroke and preeclampsia ([@b13-ijo-51-01-0257],[@b14-ijo-51-01-0257]). Various active constituents have been isolated, such as alkaloids, flavonoids, sterols, coumarins, terpenoids and terpenoid glycosides ([@b15-ijo-51-01-0257]). A number of alkaloids in uncaria are used for cancer treatment and adjuvant chemotherapy, among which rhynchophylline (Rhy), isorhynchophylline (Irhy), corynoxeine (Cory), isocorynoxeine (Icory), hirsutine (HS) and hirsuteine (HST) are the major components. The exact antitumor activities and mechanisms of these uncaria alkaloids remain to be identified.

Herein, six uncaria alkaloids were preliminarily screened, and all these compounds exhibited potential MDR-reversal activity. Among them, Icory had the strongest activity. Therefore, we used Icory as a representative compound to study in depth its MDR-reversal activity and to further clarify its underlying mechanisms.

Materials and methods
=====================

Chemicals and reagents
----------------------

Rhy, Irhy, Cory, Icory, HS and HST were purchased from YUANYE (Shanghai, China), and their purities determined by HPLC were \>98%. VCR, DOX, paclitaxel and cisplatin were purchased from Selleck Chemicals (Houston, TX, USA). The Pgp-Glo™ assay kit was purchased from Promega (Fitchburg, WI, USA). The Quanscript RT kit and Multi-PCR kit were obtained from Multisciences (Hangzhou, Zhejiang, China). Mouse anti-ABCB1 antibody was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Mouse anti-β-actin antibody was acquired from Cell Signaling Technology (Beverly, MA, USA). Verapamil (VRP), Fumitremorgin C (FTC), Mitoxantrone (MX), MK-571, 3-(4,5-dimethylthiazol-yl)-2,5-diphenyllapatinibrazolium bromide (MTT), 2-(4-amidinophenyl)-6-indolecarbamidene dihydrochloride (DAPI), dimethyl sulfoxide (DMSO) and other chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA).

Cell lines and cell culture
---------------------------

The human hepatocellular carcinoma cell line HepG2 and the ABCB1-overexpressing cell line HepG2/ADM were kindly provided by Professor Kwok-Pui Fung (The Chinese University of Hong Kong, Hong Kong, China). The human breast cancer cell line MCF-7 and its doxorubicin-selected ABCB1-overexpressing cell line MCF-7/ADR were previously provided by Professor Li-Wu Fu (Sun Yat-Sen University, Guangzhou, China). The human primary embryonic kidney cell line HEK293 and its pcDNA3.1, ABCB1-transfected cell lines HEK293/pcDNA3.1 and HEK293/MRP1 were kindly provided by Dr Suresh Ambudkar (NCI, NIH, Bethesda, MD, USA). The colorectal cancer cell line S1 and ABCG2 overexpressing S1-M1-80 cells were kindly provided by Dr Susan Bates and Robert Robey (NCI, NIH, Bethesda, MD, USA). All of the cell lines were maintained in DMEM supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin in a humidified incubator containing 5% CO~2~ at 37°C. HepG2/ADM and MCF-7/ADR cells were cultured in media containing 1.2 *μ*M DOX to maintain their resistance features.

Cytotoxicity determination by the MTT assay
-------------------------------------------

The MTT assay was used to detect the cytotoxic activity and MDR-reversal activity of uncaria alkaloids and VRP. Cells (5×10^3^/well) were distributed into 96-well plates and were maintained overnight. For the cytotoxicity experiments, cells were cultured with different concentrations of uncaria alkaloids (Rhy, Irhy, Cory, Icory, HS and HST) or with VRP for 72 h. To evaluate the reversal activity of these alkaloids, various concentrations of the chemotherapeutic drugs with or without alkaloids at sub-toxic concentrations were added into the designated wells. After 72 h of incubation, 30 *μ*l of MTT (5 mg/ml) was added to each well, and the plates were further incubated at 37°C for 4 h. The medium was then removed, and 100 *μ*l of DMSO was added into each well to dissolve the formazan crystals. The absorbance was read at 570 nm using a DTX 880 Multimode Detector (Beckman Coulter, Brea, CA, USA). The IC~50~ value was calculated from the survival curves using GraphPad Prism 5.0 software. The reversal fold was calculated by dividing the IC~50~ of antineoplastic agents alone by the IC~50~ of antineoplastic agents in the presence of alkaloids. VRP was used as a positive control.

Microscopic observation of intracellular DOX
--------------------------------------------

HepG2/ADM and MCF-7/ADR cells were seeded into 35-mm dishes for 24 h before being pretreated with Icory or VRP for 2 h, then 10 *μ*M DOX were added and further co-incubated with modulators for 2 h. Subsequently, the cells were washed with PBS and fixed with 4% paraformaldehyde. DAPI was used to stain the nuclei. Cellular DOX fluorescence was detected by fluorescence microscopy (Axio Imager A2, Zeiss, Jena, Germany).

DOX accumulation assay
----------------------

To measure the accumulation of DOX, 2×10^4^ cells/well were seeded in 96-well plates for 24 h. Cells were pretreated with Icory (25 and 50 *μ*M) or VRP (50 *μ*M) at 37°C for 2 h and were then incubated with DOX at a concentration of 10 *μ*M in the absence or presence of modulators for 2 h at 37°C. Subsequently, the medium was discarded, and the cells were washed three times with ice-cold PBS and soaked in 50 *μ*l of PBS. The fluorescence value of DOX was detected using a DTX 880 Multimode Detector (Beckman Coulter), and the excitation and emission wavelengths of DOX were 488 and 535 nm, respectively.

DOX efflux assay
----------------

Cells (5×10^3^ per well) were distributed into 96-well plates and incubated for 24 h before being pretreated with 25 *μ*M DOX at 37°C for 2 h, after which time the cells were supplemented with reversal agents (Icory or VRP). After various time points (0, 30, 70, 130 min), the cell culture supernatant was discarded, and the cell cultures were immediately washed three times with ice-cold PBS. The cells were fixed with paraformaldehyde for the detection of radioactivity, in a routine manner.

Real-time fluorescence quantitative PCR assay
---------------------------------------------

A real-time fluorescence quantitative PCR (qRT-PCR) assay was used to determine the mRNA expression of ABCB1. HepG2/ADM or MCF-7/ADR cells (5×10^5^/well) were seeded in 6-well plates and were treated with various concentrations of Icory for 24 h or 48 h. Total RNA was then collected using a TRIzol kit (Qiagen, Hilden, Germany) according to the manufacturer\'s protocol. cDNA was reverse transcribed from 1 *μ*g of total RNA using a reverse transcription kit (Roche, Mannheim, Germany), and the forward and reverse primers used in the qRT-PCR were as follows: 5′-CAGAGTCAAGGAGCATGGCA-3 (MDR1 forward primer), 5′-TCAGAGTTCACTGGCGCTTT-3 (MDR1 reverse primer); GAPDH-F: 5′-GAAGGTGAAGGTCGGAGTC-3′, GAPDH-R: 5′-GAAGATGGTGATGGGATTTC-3′. Amplification was performed according to the instructions for the SYBR Green Master Mix (Roche) using a Roche LightCycler (Basel, Basel-Stadt, Switzerland). PCR was performed at 95°C for 10 sec of initial denaturation and then at 60°C for 20 sec, 72°C for 20 sec for 45 cycles. Relative expression levels were calculated using the 2^−ΔΔCt^ method for qRT-PCR.

Western blotting
----------------

Cells were collected after incubation with 25 or 50 *μ*M Icory for 24 or 48 h, lysed with RIPA lysis buffer (10 mM Tris HCl pH 7.5, 1 mM EDTA, 0.1% SDS, 150 mM NaCl, 1% Triton X-100 and 0.01% leupeptin) for 0.5 h and centrifuged at 14,000 × g at 4°C for 10 min. The supernatant was stored at −80°C until gel electrophoresis. Protein concentrations were detected using the bicinchoninic acid (BCA)-based protein assay (Thermo Scientific, Rockford, IL, USA). A total of 30 *μ*g of protein from the cell lysates was separated by 10% SDS-PAGE and transferred onto a PVDF membrane (Millipore, Billerica, MA, USA). The membranes were blocked in blocking buffer (5% non-fat dry milk in TBST buffer) and were then immunoblotted with ABCB1 antibody (1:500) overnight at 4°C. After washing three times with TBST buffer, the membranes were further incubated for 1 h at room temperature with HRP-conjugated secondary antibody (1:2,000). Protein detection on the blot was performed using an enhanced chemiluminescence detection kit (Beyotime Institute of Biotechnology, Shanghai, China).

Immunofluorescence assay
------------------------

Cells (1×10^5^) were incubated with 50 *μ*M of Icory for 24 and 48 h, respectively. Then cells were washed thrice with PBS and fixed with 4% paraformaldehyde for 20 min at room temperature. Subsequently, cells were blocked with 5% BSA for 1 h at room temperature, followed by monoclonal antibody (1:50) against ABCB1 at 4°C overnight. After that cells were rinsed with PBS and then stained with Alexa fluor 488-conjugated goat anti-mouse secondary antibody (1:500) for 1 h at room temperature in the dark. DAPI (1 *μ*g/*μ*l) was used to counterstain the nuclei. Images were taken by a confocal microscope (LSM 700, Zeiss) at 495-nm excitation and 519-nm emission wavelength (FITC 488) and 340-nm excitation and 488-nm emission wavelength (DAPI).

ABCB1 ATPase assay
------------------

The ABCB1-Glo™ ATPase assay was used to detect the effects of Icory on recombinant human ABCB1. The ABCB1 ATPase inhibitor Na~3~VO~4~ (250 *μ*M), VRP (500 *μ*M) and Icory (25, 50 and 100 *μ*M) were prepared and added to untreated white polystyrene 96-well plates, and then ABCB1-containing membranes were added to each well and incubated at 37°C for approximately 5 min. The reactions were initiated by adding 10 *μ*l of MgATP (25 mM) and were then incubated for 40 min at 37°C. The plate was removed from 37°C, and luminescence was initiated by adding 50 *μ*l of Detection Reagent. Next, the plate was incubated at room temperature for 20 min to stabilize the luminescent signal, and the luminescence was read on a DTX880 Multimode Detector (Beckman Coulter).

Duration of MDR-reversal effect assay
-------------------------------------

The durations of Icory and VRP reversal effects were measured as previously described ([@b16-ijo-51-01-0257]). HepG2/ADM cells (5×10^3^ cells) were pretreated with Icory or VRP at a concentration of 50 *μ*M for 24 h. In the durative group, the MDR modulators were removed, and the cells were washed with PBS and then treated with various concentrations of DOX. In the unwashed group, different concentrations of DOX were added to retain the MDR modulators. Cell viability was detected using the MTT assay, as described above.

Docking assay
-------------

The crystal structure of mouse ABCB1 was obtain from the protein data bank (PDB entry code: 3G5U), which was further prepared by using Surflex-Dock in Sybyl 8.0. Halved structure of 3G5U was used as the receptor in the following docking experiment. The low-energy 3D structure of Icory and VPR was generated based on the random conformational search with restricted chirality, which was performed using the standard MMFF94s molecular mechanics force field and MMFF94 charge. Optimized 3D structures of VRP and Icory were docked into the binding site of ABCB1 by using Surflex-dock in Sybyl 8.0 to simulate the binding modes. The best docking score was used in the docking process to identify the preferable conformation of Icory and ABCB1. Icory and VRP were docked into the binding site of ABCB1 according to their best docking scores, and further interactions and binding energy were analyzed.

Data analysis
-------------

Every experiment was repeated at least three times, and values are shown as the mean ± SD. The data were analyzed using GraphPad Prism 5.0, and the differences between two groups were analyzed by Student\'s t-test. The P-value significance threshold was set at P\<0.05.

Results
=======

Cytotoxicity of uncaria alkaloids and VRP in sensitive and resistant cells
--------------------------------------------------------------------------

The sub-cytotoxic concentrations (cell survival rate of at least 90%) of uncaria alkaloids (Rhy, Irhy, Cory, Icory, HS and HST) and VRP in sensitive and resistant cell lines were determined. A concentration of 50 *μ*M rather than 100 *μ*M met the requirement for Rhy, Irhy, Cory and Icory ([Fig. 1B](#f1-ijo-51-01-0257){ref-type="fig"}). A surprising finding was that HS and HST showed potential antitumor activity in HepG2/ADM cells and in the sensitive parental cell line HepG2, and their sub-cytotoxic concentrations fell to 3 *μ*M ([Fig. 1B](#f1-ijo-51-01-0257){ref-type="fig"}). To further test the reversal activity and to explore the underlying mechanisms of Icory, a pair of DOX-resistant and -sensitive cell lines, MCF-7/ADR and MCF-7, were chosen. Similarly, a non-toxic concentration of Icory in MCF-7/ADR and MCF-7 cells was 50 *μ*M ([Fig. 1C](#f1-ijo-51-01-0257){ref-type="fig"}). Therefore, concentrations of 25 and 50 *μ*M Icory were used for the subsequent MDR-reversal experiments. As a positive control, VRP at 50 *μ*M showed no toxicity to the four cell lines ([Fig. 1D](#f1-ijo-51-01-0257){ref-type="fig"}).

Uncaria alkaloids sensitize ABCB1-overexpressing cells to DOX
-------------------------------------------------------------

To investigate whether uncaria alkaloids had the ability to reverse ABCB1-mediated MDR, DOX was used as the anticancer drug in HepG2/ADM cells and in the parental HepG2 cells. The IC~50~ values of DOX with or without uncaria alkaloids in the two cell lines are shown in [Table I](#tI-ijo-51-01-0257){ref-type="table"}. The results showed that each of the uncaria alkaloids variously increased the sensitivity of HepG2/ADM cells to DOX and that Icory exhibited the most potent activity, with a reversal-fold value of 31.09. Thus, Icory was chosen for the subsequent experiments as a representative of uncaria alkaloids.

Icory reverses ABCB1-overexpressing cell resistance to DOX, VCR and paclitaxel
------------------------------------------------------------------------------

The modulating effect of Icory was further examined in MDR cancer cell lines (HepG2/ADM and MCF-7/ADR) and in their corresponding sensitive cell lines (HepG2 and MCF-7). The IC~50~ values of anticancer drugs (DOX, VCR, paclitaxel and cisplatin) in the ABCB1-overexpressing cells and in the parental cells with or without Icory are summarized in [Table II](#tII-ijo-51-01-0257){ref-type="table"}. Consistent with the preliminary screening, Icory greatly enhanced the activity of DOX in DOX-resistant HepG2/ADM and MCF-7/ADR cells but not in their parental cell lines. Icory also increased the sensitivity of HepG2/ADM and MCF-7/ADR cells to VCR and paclitaxel, whereas this effect did not occur in their respective parental cell lines. However, the IC~50~ values of cisplatin were not altered in any of the cell lines when combined with Icory or VRP ([Fig. 2](#f2-ijo-51-01-0257){ref-type="fig"}). In the MCF-7/ADR cell line, Icory strikingly enhanced the toxicity of VCR and paclitaxel with 584.10 and 336.36 reversal-fold values, respectively. Collectively, these results indicated that Icory significantly reverses ABCB1-overexpressing cell resistance to DOX, VCR and paclitaxel.

Icory does not reverse ABCC1- or ABCG2-mediated MDR
---------------------------------------------------

Overexpressed ABCC1 and ABCG2 are two important transporters in cancer MDR, and we further examined whether Icory exerted reversal effects on ABCC1- and ABCG2-overexpressing cell lines. First, we confirmed that Icory at 50 *μ*M showed no toxicity to the HEK293/MRP1 and S1-M1-80 cell lines or their parental cell lines ([Fig. 3A](#f3-ijo-51-01-0257){ref-type="fig"}). The ABCC1 modulator MK-571 significantly reversed the drug resistance of HEK293/MRP1 cells. However, we did not observe similar activity for Icory in HEK293/MRP1 cells when combined with the ABCC1 substrate VCR ([Fig. 3B](#f3-ijo-51-01-0257){ref-type="fig"} and [Table III](#tIII-ijo-51-01-0257){ref-type="table"}). Analogously, Icory had no reversal activity toward ABCG2-mediated MDR, as the IC~50~ values of MX in ABCG2-overexpressing S1-M1-80 cells and their parental S1 cells were unchanged when co-treated with Icory. In stark contrast to Icory, FTC sensitized S1-M1-80 cells to MX at a non-toxic concentration of 10 *μ*M ([Fig. 3C](#f3-ijo-51-01-0257){ref-type="fig"} and [Table IV](#tIV-ijo-51-01-0257){ref-type="table"}). These results suggest that Icory may be a specific ABCB1 modulator.

Icory increases the intracellular accumulation of DOX in ABCB1-overexpressing cells
-----------------------------------------------------------------------------------

To investigate the reversal mechanism by which Icory sensitizes ABCB1-mediated MDR in cancer cells, the accumulation level of DOX in ABCB1-overexpressing cells was measured. As shown in [Fig. 4A](#f4-ijo-51-01-0257){ref-type="fig"}, Icory enhanced the intracellular fluorescence intensity of DOX in HepG2/ADM and MCF-7/ADR cells. A quantitation of the fluorescence intensity is presented with the images ([Fig. 4A](#f4-ijo-51-01-0257){ref-type="fig"}, bottom). Furthermore, a significant increase in the DOX intensity in the presence of Icory was detected using a Multimode Detector ([Fig. 4B](#f4-ijo-51-01-0257){ref-type="fig"}). The increase in DOX intensity mediated by Icory was less than that of the positive-control VRP, in accord with their relative reversal activities. These results showed that Icory treatment elevates the intracellular DOX concentration in ABCB1-overexpressing cells.

Icory inhibits the intracellular efflux of DOX in ABCB1-overexpressing cells
----------------------------------------------------------------------------

To investigate whether Icory can inhibit the efflux activity of ABCB1, a DOX efflux assay was performed with HepG2/ADM cells. As shown in [Fig. 4C](#f4-ijo-51-01-0257){ref-type="fig"}, the pumping rate of DOX in HepG2/ADM cells treated with Icory was lower than that in untreated cells. Consistent with their activities, VRP showed a stronger effect than Icory on the retention level of intracellular DOX. The results suggest that Icory promotes DOX accumulation by blocking DOX efflux in ABCB1-overexpressing cells.

Icory has no effect on the expression of ABCB1
----------------------------------------------

Considering that blocking ABCB1 transport and downregulating ABCB1 expression would both result in the retention of intracellular DOX, we further examined the mRNA and protein expression levels of ABCB1. As shown in [Fig. 5A and B](#f5-ijo-51-01-0257){ref-type="fig"}, HepG2/ADM and MCF-7/ADR cells were treated with Icory at 25 *μ*M and 50 *μ*M for two time periods (24 and 48 h). However, no significant alterations were observed in the ABCB1 mRNA or protein levels, confirming that the reversal effect of Icory is not related to the downregulation of ABCB1 expression.

Icory does not alter the localization of ABCB1
----------------------------------------------

In order to further investigate whether Icory can change cellular localization of ABCB1, the immunofluorescence assay was conducted in HepG2/ADM cells. As shown in [Fig. 5C](#f5-ijo-51-01-0257){ref-type="fig"}, Icory treatment for 24 or 48 h at 50 *μ*M did not alter the cellular localization of ABCB1.

Icory stimulates ABCB1 ATPase activity
--------------------------------------

We reasoned that Icory might induce DOX retention by inhibiting the efflux function of ABCB1. Thus, an ABCB1 ATPase activity assay was performed to investigate whether Icory is a substrate of ABCB1. According to the Pgp-Glo™ assay system, ABCB1 is an ATP-dependent drug efflux pump, and ATP consumption reflects its transport activity. As shown in [Fig. 5D](#f5-ijo-51-01-0257){ref-type="fig"}, similar to VRP, Icory strikingly stimulated ABCB1 ATPase activity in a concentration-dependent manner. The results indicate that Icory is likely a substrate of ABCB1 that blocks its efflux function.

The MDR-reversal effect of Icory depends on its durative concentration
----------------------------------------------------------------------

A characteristic of an ABCB1 competitive inhibitor is that the reversal effect disappears following drug washout. The persistence and reversibility of MDR-reversal effects can be assessed in a therapeutically relevant way by assaying residual activity after washout of the reversal agents. As shown in [Fig. 5E](#f5-ijo-51-01-0257){ref-type="fig"}, the reversal effect of Icory on HepG2/ADM cells was no longer present after the washout of Icory, similar to VRP, a known ABCB1 competitive inhibitor. These results suggest that Icory may be a competitive inhibitor of ABCB1.

Molecular docking model of Icory binding to ABCB1
-------------------------------------------------

The above results suggested that the reversal effect of Icory may occur through a direct interaction with ABCB1. To further explore the probable binding conformation with ABCB1, Icory was computationally docked into ABCB1. As shown in [Fig. 6](#f6-ijo-51-01-0257){ref-type="fig"}, Icory bound to ABCB1 at the same site as VRP but did not completely overlap. The residues of ABCB1 surrounding Icory were LEU64, VAL861, ILE864, ALA865, ALA867, GLY868, THR941, GLN942, MET944, MET945, SER948, TYR949, ALA981, VAL984. Among these residues, LEU64, VAL861, ILE864, ALA865, GLY868, THR941, GLN942, MET945, TYR949, ALA981, VAL984 were also around VRP. These residues were well consistent with the key residues. The docking result further confirmed that Icory binds to ABCB1 at the same site as VRP but that the binding site does not completely overlap with that of VRP. In addition, the binding energy between icory or VRP and ABCB1 was 46.55 kcal/mol and 123.5 kcal/mol, respectively, which suggested the affinity of Icory binding to ABCB1 may be weaker than that of VRP.

Discussion
==========

In the past three decades, researchers have devoted much effort to the search for effective and clinically applicable ABCB1 modulators. Searching for more effective, low-toxicity ABCB1 modulators from traditional Chinese medicine has become a promising road. Uncaria alkaloids, the major naturally active substances of uncaria, were reported to have anticancer activity, including cytotoxicity and MDR-reversal effects. Uncaria is a common traditional Chinese medicine, and there are different constituents and contents with the change of uncaria species. The six alkaloids are principal components which exist in great quantities ranging from 0.1% to 1% in uncaria ([@b17-ijo-51-01-0257],[@b18-ijo-51-01-0257]). In this investigation, we demonstrated for the first time that all six alkaloids significantly reduced the resistance of ABCB1-mediated MDR cells to chemotherapeutics, also, the total uncaria alkaloid extract exhibits MDR reversal activity with 8.74 reversal-fold value in HepG2/ADM cells when combined with DOX.

Furthermore, HS and HST showed higher cytotoxicity against ABCB1-overexpressing cells than the other four agents, likely due to differences in their chemical structures. Compared with HS and HST, which are non-oxindole alkaloids, Rhy, Irhy, Cory and Icory are oxindole alkaloids characterized by oxidization at the indole ring, this distinction may explain their weaker toxicity than HS and HST. By contrast, Rhy/Irhy and Cory/Icory are two pairs of isomerides, and they contain a spirocyclic ring on the indole ring but have varying stereochemistry on the ring skeleton, which may be connected with their MDR-reversal effect. Therefore, the selection of a suitable uncaria alkaloid chemotype may be very important for MDR-reversal activity because it differs from the chemical structure and conformation.

Since some MDR transporter inhibitors not only bind to ABCB1 but also influence the function of other ABC transporters, they do not exhibit specificity. Icory sensitized ABCB1-overexpressing cells to DOX, VCR and paclitaxel, but it did not have similar effect on their parental cells. Icory did not alter the sensitivity of ABCB1-overexpressing cells to cisplatin, which is not an ABCB1 substrate, suggesting that the reversal potency of Icory is closely associated with ABCB1. As previously reported, ABCC1 can remove internal noxious substances, including important endogenous substances, xenobiotics and their metabolites, to protect normal tissue from cytotoxicity ([@b19-ijo-51-01-0257]). ABCG2 confers a protective effect to hypoxic cells, and ABCG2 is also responsible for cellular homeostasis and influences medicine absorption, distribution, and excretion in the human body ([@b20-ijo-51-01-0257]-[@b23-ijo-51-01-0257]). Thus, inhibiting ABCC1 and ABCG2 may disrupt cellular homeostasis and normal drug metabolism, potentially causing toxicity and other side effects. Fortunately, Icory had no significant reversal effects on ABCC1- and ABCG2-overexpressing cells or their parental cells. Therefore, the use of Icory would minimize any side effects caused by the inhibition of ABCC1 and ABCG2 transporters.

Icory significantly increased intracellular DOX accumulation in ABCB1-overexpressing cells, and the efflux assay confirmed that the DOX accumulation was due to the inhibition of ABCB1 efflux function. As previously reported, downregulation of ABCB1 expression would result in the inhibition of ABC transporter-mediated efflux ([@b24-ijo-51-01-0257]). However, our results showed that after treatment with Icory, neither the expression levels nor localization of ABCB1 in HepG2/ADM or MCF-7/ADR cells were significantly altered, suggesting that Icory influences the drug transport function rather than the expression and localization of ABCB1. It is well known that the substrates of ABCB1 activate the ATPase to hydrolyze ATP and provide the energy needed by the ABCB1 transporter. Therefore, a change in ABCB1 ATPase activity directly reflects whether a drug is the substrate of ABCB1. Our results showed that Icory markedly stimulated the activity of the ABCB1 ATPase in a concentration-dependent manner, indicating that Icory may be a substrate of the ABCB1 transporter. As previously reported, an ATP modulator can act as a competitive inhibitor by binding to the drug-binding pocket in TMD or as a non-competitive inhibitor by suppressing ATP binding by nucleotide-binding domains ([@b25-ijo-51-01-0257]). Our results showed that the reversal activity of Icory disappeared after being washed out, resembling the positive-control VRP and indicating that Icory acts as a competitive inhibitor of ABCB1. Moreover, our molecular docking analysis indicated that the residues of ABCB1 surrounding Icory also partly overlapped with those around VRP. The result further supports the idea that Icory binds to important binding sites of ABCB1 and acts as a substrate of ABCB1.

Icory has several particular characteristics comparing to other MDR inhibitors. The six uncaria alkaloids all derive from the low toxic traditional Chinese medicine uncaria, which has been used in clinic for a long time, and they exist in great quantities in uncaria; Icory can specifically reverse ABCB1 other than ABCC1 or ABCG2 transporter-mediated MDR cancer. However, compared with the tyrosine kinase inhibitors, the reversal activity of Icory is still weaker. Thus, in order to improve the efficacy of uncaria alkaloid, further structural modification studies are warranted.

In this study, we demonstrated that uncaria alkaloids, including Rhy, Irhy, Cory, Icory, HS and HST, reverse ABCB1-mediated MDR at non-toxic concentrations. Among them, Icory showed the strongest activity. Instead of altering the expression level and localization of ABCB1, Icory acts as a substrate of ABCB1, competitively binding to the drug-binding sites of ABCB1 and thus inhibiting its drug efflux function. The uncaria alkaloids exhibit potential to be reversal agents for ABCB1 transporter-mediated MDR, and further *in vivo* studies are warranted.
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![Cytotoxicity assays of individual uncaria alkaloids (Rhy, Irhy, Cory, Icory, HS and HST) and VRP in ABCB1-overexpressing cells and in their parental cells. (A) The chemical structures of Rhy, Irhy, Cory, Icory, HS and HST. (B) The percentage of surviving cells was measured after treatment with Rhy, Irhy, Cory, Icory, HS and HST for 72 h in ABCB1-overexpressing cells and their parental cells, namely, HepG2/ADM and HepG2 cells, respectively. (C) The cell survival percentage was measured after treatment with Icory for 72 h in MCF-7/ADR and MCF-7 cells. (D) The cell survival percentage was measured after treatment with VRP for 72 h in HepG2/ADM, HepG2 cells, MCF-7/ADR and MCF-7 cells. The results were presented as the means ± SD of three independent experiments performed in six replicates.](IJO-51-01-0257-g00){#f1-ijo-51-01-0257}

![Icory sensitizes HepG2/ADM and MCF-7/ADR cells, but not their parental cells, to DOX, VCR and paclitaxel. The viability of HepG2/ADM, MCF-7/ADR cells and their parental cells treated with DOX (A), VCR (B), paclitaxel (C) and cisplatin (D) in the absence or presence of Icory (25 and 50 *μ*M) was detected by the MTT assay. VRP (50 *μ*M) was used as a positive inhibitor of ABCB1. The results are presented as the means ± SD of three independent experiments performed in six replicates.](IJO-51-01-0257-g01){#f2-ijo-51-01-0257}

![Icory does not sensitize ABCC1- or ABCG2-overexpressing cells to MX or VCR. (A) The percentage of surviving cells was measured after treatment with Icory, MK-571 and FTC for 72 h in HEK293/MRP1, S1-M1-80 cells and their parental cells by MTT assay, respectively. (B) The viability of HEK293/MRP1 cells (left panel) and HEK293/pcDNA3.1 cells (right panel) treated with VCR in the absence or presence of Icory (25 and 50 *μ*M) was detected by the MTT assay. MK-571 (10 *μ*M) was used as a positive inhibitor of ABCC1. (C) The viability of S1-M1-80 cells (left panel) and S1 cells (right panel) treated with MX in the absence or presence of Icory (25 and 50 *μ*M) was detected by the MTT assay. FTC (10 *μ*M) was used as a positive inhibitor of ABCG2. The results are presented as the means ± SD of three independent experiments performed in six replicates.](IJO-51-01-0257-g02){#f3-ijo-51-01-0257}

![Icory increases the accumulation of DOX and inhibits the efflux of DOX in HepG2/ADM cells. (A) Cells were observed by fluorescence microscopy, and the representative images (top) and quantitative analysis (bottom) of DOX fluorescence are shown. DOX staining are shown in red. DAPI (blue) counter-stains the nuclei. Original amplification: 630; bar: 10 *μ*m. (B) The intracellular accumulation of DOX was measured with a DTX 880 Multimode Detector. (C) The effect of Icory on DOX efflux in HepG2/ADM cells. The intracellular DOX level was measured using a DTX 880 Multimode Detector in different periods of time (0, 30, 70 and 130 min). VRP (50 *μ*M) was used as a positive-control inhibitor of ABCB1. The results are presented as the means ± SD of three independent experiments. ^\*^P\<0.05, ^\*\*^P\<0.01 and ^\*\*\*^P\<0.001 compared with the control.](IJO-51-01-0257-g03){#f4-ijo-51-01-0257}

![Icory stimulates ABCB1 ATPase activity but does not alter ABCB1 expression or localization; the MDR-reversal effect of Icory is reversible. (A) The effect of Icory at 25 and 50 *μ*M on the mRNA expression of ABCB1 in HepG2/ADM and MCF-7/ADR cells at 24 and 48 h; GAPDH was used as an internal control. (B) Effect of Icory at 25 and 50 *μ*M on the protein expression of ABCB1 in HepG2/ADM and MCF-7/ADR cells at 24 and 48 h; β-actin was used as an internal control. (C) Effect of Icory at 50 *μ*M on the localization of ABCB1 in HepG2/ADM cells for 24 and 48 h. ABCB1 staining are shown in green. DAPI (blue) counterstains the nuclei. Original amplification, 630; bar, 10 *μ*m. (D) The effect of Icory on ABCB1 ATPase activity was detected using the Pgp-Glo™ ATPase assay kit. VRP was used as a positive-control inhibitor of ABCB1. (E) Icory had no continued MDR-reversal effect after removal. The cells were pre-incubated with or without Icory (50 *μ*M) or VRP (50 *μ*M) for 24 h; the compound was then washed out, and the cells were incubated with DOX for 72 h. The viability of the cells was tested by the MTT assay. ^\*\*\*^P\<0.001 compared with the Icory-washout group and ^\#\#\#^P\<0.001 compared with the VRP-washout group. Each point represents the mean ± SD of at least three independent experiments performed in triplicate. ^\*^P\<0.05, ^\*\*^P\<0.01 and ^\*\*\*^P\<0.001 compared with the control.](IJO-51-01-0257-g04){#f5-ijo-51-01-0257}

![Docking analysis of Icory and VRP binding to ABCB1. (A) The binding mode and position of Icory and VRP with ABCB1. The residual amino acids around Icory (B) and VRP (C). Key residues are labeled.](IJO-51-01-0257-g05){#f6-ijo-51-01-0257}

###### 

Reversal activity of six uncaria alkaloids in HepG2/ADM cells and their parental cells.

  Treatments         IC~50~ ± SD[a](#tfn1-ijo-51-01-0257){ref-type="table-fn"} (*μ*M) (fold-reversal[b](#tfn2-ijo-51-01-0257){ref-type="table-fn"})   
  ------------------ -------------------------------------------------------------------------------------------------------------------------------- ----------------------
  DOX                78.5314±9.7768 (1.00)                                                                                                            0.3357±0.0193 (1.00)
  \+ Rhy 50 *μ*M     5.4859±2.7101 (14.32)                                                                                                            0.3852±0.1186 (0.87)
  \+ Irhy 50 *μ*M    3.9646±1.1056 (19.81)                                                                                                            0.3678±0.0261 (0.91)
  \+ Cory 50 *μ*M    5.2865±0.7767 (14.86)                                                                                                            0.3278±0.1221 (1.02)
  \+ Icory 50 *μ*M   2.5256±0.6897 (31.09)                                                                                                            0.3653±0.0849 (0.92)
  \+ HS 3 *μ*M       15.2977±0.7666 (5.13)                                                                                                            0.3982±0.0796 (0.84)
  \+ HST 3 *μ*M      14.3615±2.0456 (5.47)                                                                                                            0.4124±0.0153 (0.81)

Data in the table are shown as means ± SD of three independent experiments performed in six replicates.

The fold-reversals are calculated as IC~50~ for cells with the anticancer drug in the absence of inhibitors divided by that in the presence of inhibitors.

###### 

Reversal effect of Icory on HepG2/ADM, MCF-7/ADR and their parental sensitive cells.

  Treatments         IC~50~ ± SD[a](#tfn3-ijo-51-01-0257){ref-type="table-fn"} (*μ*M) (fold-reversal[b](#tfn4-ijo-51-01-0257){ref-type="table-fn"})                                                     
  ------------------ -------------------------------------------------------------------------------------------------------------------------------- ----------------------- ------------------------- -----------------------
  DOX                78.5314±9.7768 (1.00)                                                                                                            0.3357±0.0193 (1.00)    27.9157±0.8581 (1.00)     0.1921±0.0184 (1.00)
   + Icory 25 *μ*M   9.3748±0.6148 (8.38)                                                                                                             0.3728±0.0467 (0.90)    13.8451±0.5140 (2.02)     0.1373±0.0064 (1.39)
   + Icory 50 *μ*M   2.5256±0.6897 (31.09)                                                                                                            0.3653±0.0849 (0.92)    2.6711±0.6350 (10.45)     0.1913±0.0414 (1.00)
   + VRP 50 *μ*M     1.1914±0.2304 (65.92)                                                                                                            0.3639±0.1987 (0.91)    0.6437±0.1536 (43.37)     0.1837±0.0415 (1.05)
  VCR                5.6795±0.6825 (1.00)                                                                                                             0.0125±0.0018 (1.00)    6.4485±3.7066 (1.00)      0.0035±0.0013 (1.00)
   + Icory 25 *μ*M   0.3408±0.2562 (16.67)                                                                                                            0.0128±0.0019 (0.97)    5.0590±1.3830 (1.27)      0.0043±0.0003 (0.82)
   + Icory 50 *μ*M   0.1384±0.0988 (41.04)                                                                                                            0.0132±0.0030 (0.94)    0.0110±0.0083 (584.10)    0.0040±0.0014 (0.88)
   + VRP 50 *μ*M     0.0037±0.0001 (1525.93)                                                                                                          0.0132±0.0001 (0.94)    0.0024±0.0016 (2633.12)   0.0026±0.0007 (1.34)
  Paclitaxel         10.7748±2.2922 (1.00)                                                                                                            0.0222±0.0154 (1.00)    15.7079±2.6061 (1.00)     0.0093±0.0071 (1.00)
   + Icory 25 *μ*M   0.6820±0.3245 (15.80)                                                                                                            0.0247±0.0008 (0.90)    7.7363±0.7618 (2.03)      0.0095±0.0012 (0.98)
   + Icory 50 *μ*M   0.1462±0.0585 (73.70)                                                                                                            0.0227±0.0034 (0.98)    0.0467±0.0118 (336.36)    0.0093±0.0009 (1.01)
   + VRP 50 *μ*M     0.0105±0.0024 (1029.11)                                                                                                          0.0207±0.0054 (1.07)    0.0033±0.0010 (4783.16)   0.0100±0.0013 (0.93)
  Cisplatin          26.9154±0.08765 (1.00)                                                                                                           20.7555±0.5778 (1.00)   25.0096±1.2170 (1.00)     22.0492±1.0443 (1.00)
   + Icory 50 *μ*M   26.0751±0.6919 (1.03)                                                                                                            23.4144±3.5658 (0.87)   20.6873±3.1638 (1.21)     18.7218±6.9056 (1.18)
   + VRP 50 *μ*M     23.0622±0.0826 (1.17)                                                                                                            22.8127±1.4291 (0.91)   29.4822±3.2336 (0.85)     21.0994±4.1638 (1.05)

Data in the table are shown as means ± SD of three independent experiments performed in six replicates.

The fold-reversals are calculated as IC~50~ for cells with the anticancer drugs in the absence of inhibitors divided by that in the presence of inhibitors.

###### 

Reversal effect of Icory on HEK293/MRP1 and their parental sensitive cells.

  Treatments          IC~50~ ± SD[a](#tfn5-ijo-51-01-0257){ref-type="table-fn"} (*μ*M) (fold-reversal[b](#tfn6-ijo-51-01-0257){ref-type="table-fn"})   
  ------------------- -------------------------------------------------------------------------------------------------------------------------------- ----------------------
  VCR                 4.2113±1.8257 (1.00)                                                                                                             0.0211±0.0062 (1.00)
   + Icory 25 *μ*M    6.0003±1.1998 (0.70)                                                                                                             0.0199±0.0055 (1.06)
   + Icory 50 *μ*M    4.5762±2.0726 (0.92)                                                                                                             0.0189±0.0089 (1.12)
   + MK-571 10 *μ*M   0.1255±0.9248 (33.56)                                                                                                            0.0201±0.0057 (1.05)

Data in the table are shown as means ± SD of at least three independent experiments performed in six replicates.

The fold-reversals are calculated as IC~50~ for cells with the anticancer drugs in the absence of inhibitors divided by that in the presence of inhibitors.

###### 

Reversal effect of Icory on SI-M1-80 and their parental sensitive cells.

  Treatments         IC~50~± SD[a](#tfn7-ijo-51-01-0257){ref-type="table-fn"} (*μ*M) (fold-reversal[b](#tfn8-ijo-51-01-0257){ref-type="table-fn"})   
  ------------------ ------------------------------------------------------------------------------------------------------------------------------- ----------------------
  MX                 14.3009±0.9842 (1.00)                                                                                                           0.0135±0.0074 (1.00)
   + Icory 25 *μ*M   6.3245±0.1678 (1.72)                                                                                                            0.0129±0.0092 (1.05)
   + Icory 50 *μ*M   8.3785±1.3797 (1.72)                                                                                                            0.0142±0.0080 (0.95)
   + FTC 10 *μ*M     0.4222±0.0231 (33.87)                                                                                                           0.0126±0.0057 (1.07)

Data in the table are shown as means ± SD of at least three independent experiments performed in six replicates.

The fold-reversals are calculated as IC~50~ for cells with the anticancer drugs in the absence of inhibitors divided by that in the presence of inhibitors.

[^1]: Contributed equally
